ArticleSleep2025
Genome-wide, integrative analysis implicates exosome-derived microRNA dysregulation in chronic insomnia.
Article in Sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Scoping review on the relationship between microRNAs (miRNAs) and short sleep disorder or insomnia with short sleep duration.Sleep medicine: X · 2026Article
- Epigenetic Insights and Exosome-Based Therapeutics for Insomnia: Bridging Sleep Biology and Precision Medicine.Molecular neurobiology · 2026Review
- Gut microbiota: a new target for the prevention and treatment of insomnia using Chinese herbal medicines and their active components.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
STUDY
objectivesInsomnia, characterized by difficulty in initiating and sustaining sleep or waking prematurely without the ability to return to sleep, affects approximately 30% of the population. The underlying mechanisms of insomnia remain unclear, and the objective diagnostic measures are scarce. It is an opportunity to explore the roles of peripheral blood exosomal miRNAs in insomnia patients.
methodsExosomal miRNAs were isolated from 20 insomnia patients and an equal number of healthy individuals. A comprehensive genome-wide miRNA expression analysis was conducted to identify differential miRNAs between the two groups. To evaluate the diagnostic potential of these miRNAs, receiver-operating characteristic (ROC) curves were employed. Furthermore, Gene Ontology enrichment analysis and Kyoto Encyclopedia of Genes and Genomes pathway analysis were performed on the target genes of differential exosome miRNA to explore their regulated signaling pathways and molecular functions.
resultsWe identified 51 differentially expressed miRNAs. Among these, miR-182-5p and miR-451a were markedly downregulated in patients as evidenced by their area-under-the-curve values. The areas under the ROC curves and 95% confidence intervals (CIs) of miR-182-5p and miR-451a in predicting the possibility of chronic insomnia patients were 0.863 (95% CI = 0.75 to 0.97) and 0.813 (95% CI = 0.68 to 0.95). Coexpression network analysis and enrichment analysis of miRNA target genes shed light on the molecular pathophysiology of insomnia, including autophagy and mitophagy.
conclusionsThese findings suggest that peripheral blood exosomal miRNAs may serve as potential noninvasive biomarkers for insomnia diagnosis and provide new insights into the molecular mechanisms underlying this sleep disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.